Novartis Divests Tension Headache Products in U.S.
February 12, 2003 03:15 ET
|
Novartis
BASEL, Switzerland, Feb. 12, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has sold the U.S. rights for its Fioricet(R) and Fiorinal(R) product lines to Watson Pharmaceuticals,...
Australian Pharmaceutical Industries to Implement New Core Application System from Intentia
January 23, 2003 08:51 ET
|
Intentia
STOCKHOLM, Sweden and SYDNEY, Australia, Jan. 23, 2003 (PRIMEZONE) -- Intentia International AB (publ.) (Stockholm:INTb) (Other OTC:IAINF), one of the world's most successful suppliers of enterprise...
Innogenetics' Outlook for 2003 -- Enhanced Financial Prospects and Promising New Therapeutic Developments
January 15, 2003 02:21 ET
|
Innogenetics
GENT, Belgium, Jan. 15, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced the preliminary indications of its year 2002 financial results, offered an initial outlook for 2003 and...
Pyrosequencing to Distribute Corbett Products in the U.S.
January 14, 2003 08:30 ET
|
Pyrosequencing
UPPSALA, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Pyrosequencing AB (Stockholm:PYROa) (Other OTC:PYRSF) today reported that the Company signed an agreement to distribute Corbett Research's full line of...
Biovitrum AB Signs an Agreement with Lundbeck to Produce Protein Therapeutics
January 14, 2003 04:13 ET
|
Biovitrum AB
STOCKHOLM, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Biovitrum AB today announced a commission agreement with the Danish pharmaceutical company Lundbeck A/S for the production of a protein...
Biovitrum Signs Agreement with Lundbeck to Produce Protein Therapeutics
January 14, 2003 04:08 ET
|
Biovitrum
STOCKHOLM, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Biovitrum AB today announces a commission agreement with the Danish pharmaceutical company Lundbeck A/S for the production of a protein...
Crucell Expects Charge Related to Impairment of Goodwill
December 23, 2002 03:24 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Dec. 23, 2002 (PRIMEZONE) -- Dutch antibody and vaccine company, Crucell N.V. (Nasdaq:CRXL) today announced that it expects to record a goodwill impairment charge during the...
Sectra Announces Cooperation with European Health IT Supplier Torex
December 13, 2002 03:43 ET
|
Sectra
LINKOPING, Sweden, Dec. 13, 2002 (PRIMEZONE) -- The Swedish IT- and medical technology company Sectra (Other OTC:SSBBF) (Stockholm:SECTb) signed a partnership agreement with U.K.-based Torex Health,...
Actelion Ltd.: European Commission Approval for Zavesca; European Launch of Type 1 Gaucher Treatment in spring 2003
November 26, 2002 03:41 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland and OXFORD, U.K., Nov. 26, 2002 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) and Oxford GlycoSciences Plc (LSE:OGS) (Nasdaq:OGSI) today announced that the...
Biacore Cell-Based Assay System Introduced
November 19, 2002 06:15 ET
|
Biacore
UPPSALA, Sweden, Nov. 19, 2002 (PRIMEZONE) -- Biacore International AB (Biacore) (SSE:BCOR) (Nasdaq:BCOR) today announced the introduction of its new cell-based assay system at the first of a series...